Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

New technology for cervical cancer screening.

Gong JM, Shen Y, He YX, Lei DM, Zhang Z, Li XF.

Int J Gynecol Cancer. 2012 Nov;22(9):1564-9. doi: 10.1097/IGC.0b013e318272e7e7.

PMID:
23042529
2.

[Combining high-risk human papillomavirus DNA test and cytological test to detect early cervical dysplasia].

Qian DY, Cen JM, Wang D, Zeng RH, Lin AH, Shu YH, Hong DH, Huang ZH.

Zhonghua Fu Chan Ke Za Zhi. 2006 Jan;41(1):34-7. Chinese.

PMID:
16635326
3.

Efficacy of Pap test in combination with ThinPrep cytological test in screening for cervical cancer.

Chen H, Shu HM, Chang ZL, Wang ZF, Yao HH, Zhu HM, Lu TM, Ma QY, Yang BL.

Asian Pac J Cancer Prev. 2012;13(4):1651-5.

4.

[Study on the value assessment of various screening programs regarding cervical cancer screening strategy in the rural areas of China].

Li LY, Qiao ZQ, Zhang MF, Yang JP, Bao YP, An YT, Lei J, Xiong NH, Yu XH, Zhang X, Pan QJ, Qiao YL.

Zhonghua Liu Xing Bing Xue Za Zhi. 2007 Oct;28(10):964-7. Chinese.

PMID:
18399140
5.

Determination of the diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions: preliminary data.

Tiews S, Steinberg W, Schneider W, Hanrath C.

J Clin Virol. 2009 Nov;46 Suppl 3:S11-5. doi: 10.1016/S1386-6532(09)70295-1.

PMID:
20129068
6.

[Evaluation of cobas 4800 high-risk HPV test as a tool in cervical cancer screening and cytology triage].

Chen W, Yu LL, Wang H, Fu CJ, Chen F, Cao YQ, Kang LN, Zhang X, Zhao FH, Geng L, Yu L.

Zhonghua Zhong Liu Za Zhi. 2012 Jul;34(7):543-8. doi: 10.3760/cma.j.issn.0253-3766.2012.07.014. Chinese.

PMID:
22967475
7.

Detection of human telomerase RNA gene in cervical cancer and precancerous lesions: comparison with cytological and human papillomavirus DNA test findings.

Li Y, Ye F, Lü WG, Zeng WJ, Wei LH, Xie X.

Int J Gynecol Cancer. 2010 May;20(4):631-7. doi: 10.1111/IGC.0b013e3181c50c7e.

PMID:
20686384
8.

Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico.

Salmerón J, Lazcano-Ponce E, Lorincz A, Hernández M, Hernández P, Leyva A, Uribe M, Manzanares H, Antunez A, Carmona E, Ronnett BM, Sherman ME, Bishai D, Ferris D, Flores Y, Yunes E, Shah KV.

Cancer Causes Control. 2003 Aug;14(6):505-12.

PMID:
12948281
9.

Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.

Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, Anttila A.

J Natl Cancer Inst. 2009 Dec 2;101(23):1612-23. doi: 10.1093/jnci/djp367. Epub 2009 Nov 9.

10.

Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years.

Luyten A, Scherbring S, Reinecke-Lüthge A, Braun BE, Pietralla M, Theiler K, Petry KU.

J Clin Virol. 2009 Nov;46 Suppl 3:S5-10. doi: 10.1016/S1386-6532(09)70294-X.

PMID:
20129072
11.

Role of p16(INK4a) cytology testing as an adjunct to enhance the diagnostic specificity and accuracy in human papillomavirus-positive women within an organized cervical cancer screening program.

Gustinucci D, Passamonti B, Cesarini E, Butera D, Palmieri EA, Bulletti S, Carlani A, Staiano M, D'Amico MR, D'Angelo V, Di Dato E, Martinelli N, Malaspina M, Spita N, Tintori B, Fulciniti F.

Acta Cytol. 2012;56(5):506-14. doi: 10.1159/000338979. Epub 2012 Sep 27.

PMID:
23075891
12.

[Evaluation of gene chip technology for high risk type human papillomavirus in cervical cancer screening].

Li RZ, Shi JF, Zhou QZ, Wu RF, Li N, Wu LN, Zhou YQ, Wang Q, Liu ZH, Liu B, Qiao YL.

Zhonghua Yi Xue Za Zhi. 2006 Feb 7;86(5):307-11. Chinese.

PMID:
16677522
13.

Design and methods of the evaluation of an HPV-based cervical cancer screening strategy in Mexico: The Morelos HPV Study.

Flores Y, Shah K, Lazcano E, Hernández M, Bishai D, Ferris DG, Lörincz A, Hernández P, Salmerón J; Morelos HPV Study Collaborators.

Salud Publica Mex. 2002 Jul-Aug;44(4):335-44.

PMID:
12216521
14.

Human papillomavirus (HPV) genotyping by HPV DNA chip in cervical cancer and precancerous lesions.

Lee GY, Kim SM, Rim SY, Choi HS, Park CS, Nam JH.

Int J Gynecol Cancer. 2005 Jan-Feb;15(1):81-7.

PMID:
15670301
15.

A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program.

Lazcano-Ponce E, Lörincz AT, Salmerón J, Fernández I, Cruz A, Hernández P, Mejia I, Hernández-Avila M.

Cancer Causes Control. 2010 Oct;21(10):1693-700. doi: 10.1007/s10552-010-9598-2. Epub 2010 Jul 9.

PMID:
20617376
16.

Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.

Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Forslund O, Hansson BG, Hagmar B, Johansson B, Rylander E, Dillner J.

J Natl Cancer Inst. 2009 Jan 21;101(2):88-99. doi: 10.1093/jnci/djn444. Epub 2009 Jan 13.

17.

False-positive Human Papillomavirus DNA tests in cervical screening: it is all in a definition.

Rebolj M, Pribac I, Lynge E.

Eur J Cancer. 2011 Jan;47(2):255-61. doi: 10.1016/j.ejca.2010.08.010.

PMID:
20833033
18.

HPV testing in primary screening of older women.

Cuzick J, Beverley E, Ho L, Terry G, Sapper H, Mielzynska I, Lorincz A, Chan WK, Krausz T, Soutter P.

Br J Cancer. 1999 Oct;81(3):554-8.

19.

Follow-up outcomes in a large cohort of patients with human papillomavirus-negative ASC-H cervical screening test results.

Cohen D, Austin RM, Gilbert C, Freij R, Zhao C.

Am J Clin Pathol. 2012 Oct;138(4):517-23.

20.

[Clinic value of combination of high-risk human papillomavirus test and cervical cytology test in diagnosing cervical lesions].

Zhou JN, Zhao J, Yang YJ, Liao QP.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2008 Dec;22(6):478-80. Chinese.

PMID:
19544651
Items per page

Supplemental Content

Write to the Help Desk